Integrin inhibitors reaching the clinic.
Stupp
Roger
R
Ruegg
Curzio
C
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy; D012910:Snake Venoms / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006133:Growth Substances; D016023:Integrins; D012910:Snake Venoms; C422910:Cilengitide